Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing and lunch

59P - Tumor cells-adipocytes interactions are associated with poor disease outcome in invasive lobular carcinoma

Date

12 May 2023

Session

Poster viewing and lunch

Presenters

Matteo Serra

Citation

Annals of Oncology (2023) 8 (1suppl_4): 101218-101218. 10.1016/esmoop/esmoop101218

Authors

M. Serra1, N. Occelli1, M. Rediti1, L. Collet1, F. Lifrange2, X. Wang1, D. Vincent1, G. Rouas1, L. Craciun1, D. Larsimont1, D. Venet1, M. Vikkula3, F.P. Duhoux4, L. Buisseret1, F. Rothé1, C. Sotiriou1

Author affiliations

  • 1 Institute Jules Bordet, Brussels/BE
  • 2 CHU de Liège - Sart Tilman Site, Liège/BE
  • 3 De Duve Institute UCLouvain, Woluwe-Saint-Lambert/BE
  • 4 Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Brussels/BE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 59P

Background

Invasive lobular carcinoma (ILC) is the second most common histological breast cancer (BC) subtype. Little is known regarding the tumor microenvironment (TME) that characterizes ILC. In this work, we aimed to study TME and uncover tumor and stroma cells interactions with potential clinical implication in ILC using spatial transcriptomics (ST).

Methods

We performed ST (Visium 10X Genomics®) on frozen tumor samples from 43 primary HR+, HER2- ILC patients. Nine samples were from patients who experienced disease relapse. Morphological annotation of the H&E slides relative to the ST samples was performed using QuPath software. METABRIC (HR+, HER2- ILC samples, n = 122) was used as external validation cohort.

Results

Intriguingly, morphological annotations revealed a greater co-localization at the spot level between adipocytes and cancer cells in samples from patients with relapse (p = 0.04). This area was enriched in metabolism-related pathways (padj < 0.05). To assess the prognostic implication of this co-localization, we derived a 27 gene signature by performing differential gene expression analysis between patients with vs without relapse considering the ST spots laying on the tumor-adipocytes contact area. Interestingly, our adipocytes-related signature was significantly associated with poor survival in ILC patients in METABRIC. Of note, no correlation was found between the adipocytes-related and proliferation-related signatures (including genomic grade index – GGI), which were also found to be prognostic in ILC. By combining the adipocytes-related signature with the GGI, we built a robust prognostic index that outperformed the other prognostic-related signatures (computed with genefu R package) both at the univariable (HR = 1.8, p = 3.4x10-4) and at the multivariable analysis (HR 1.7, p = 0.0016) in predicting relapse free survival.

Conclusions

To our knowledge, the adipocytes-related signature is the first prognostic signature in ILC not related to proliferation, highlighting an important implication of adipocytes in the biology of ILC. The strong prognostic power of the integrated predictor has the potential to improve prognostication in ILC. Further validation is needed.

Legal entity responsible for the study

The authors.

Funding

FNRS, Fondation Jules Bordet, Breast Cancer Research Foundation, Fondation contre le Cancer.

Disclosure

F.P. Duhoux: Financial Interests, Institutional, Advisory Board: Roche, Pfizer, AstraZeneca, Lilly, Novartis, Amgen, Daiichi Sankyo, Pierre Fabre, Gilead, Seagen, MSD; Financial Interests, Institutional, Invited Speaker: Novartis, Pfizer, MSD, Roche, MSD, Boehringer Ingelheim, Pfizer, Novartis, Lilly, AbbVie, Seagen, Gilead, AstraZeneca, Menarini, Immutep; Financial Interests, Institutional, Expert Testimony: Seagen, Novartis, MSD. C. Sotiriou: Financial Interests, Institutional, Advisory Board: Astellas, Vertex, Seattle Genetics, AMGEN, INC, Merck & Co; Financial Interests, Personal, Advisory Board: Cepheid, Puma; Financial Interests, Personal, Invited Speaker: Eisai, Prime oncology, Teva; Financial Interests, Institutional, Other, Travel: Roche; Financial Interests, Institutional, Other, Internal speaker: Genentech; Financial Interests, Personal, Other, Regional speaker: Pfizer; Financial Interests, Institutional, Invited Speaker: Exact Sciences. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.